Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients
Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients
This study represents an extension of a previous study (NCT02641431) on the acute and
 long-term benefit of epicardial ablation on elimination of both BrS-ECG pattern and VT/VF
 inducibility in 500 consecutive BrS patients.
According to previous protocol (NCT02641431), 300 additional consecutive selected patients
 having an ICD implantation will be enrolled up to a total of 500 BrS patients.
 Echocardiography with cardiac deformation analysis, three-dimensional color-coded voltage,
 activation and duration electroanatomical maps before and after ajmaline (1mg/kg in 5
 minutes) wiil determine the site and the size of the arrhythmogenic substrate as
 characterized by abnormally prolonged fragmented ventricular potentials and potential wall
 motion abnormalities. Primary endpoint will be identification and elimination of this
 electrophysiological substrate by RF applications leading to ECG pattern normalization and
 VT/VF non-inducibility before and after ajmaline. Patients will be followed up to 10 years
 after ablation by sequential 12-lead ECG and Holter recording, Echocardiography, ICD
 interrogation, VT/VF inducibility patterns before and after ajmaline test.
Inclusion Criteria:

 -  Symptomatic BrS patients with typical BrS-related symptoms (cardiac arrest or syncope)
 or without typical BrS-related symptoms (dizziness, palpitations, presyncope, dyspnea)
 ICD implantation, spontaneous or ajmaline-induced type 1 Br pattern.

 Exclusion Criteria:

 -  Age < 18 years, prior epicardial ablation, pregnancy, co-morbidities.